|
Clopivaz® Manufacturer: VAMSLERClass: Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics) |
 |
 | |
| Contents | Clopidogrel hydrogen sulfate |
| Indications | Prevention of atherosclerotic events in peripheral arterial disease, or within 35 days of MI, or within 6 mths of ischemic stroke, or (given w/ aspirin) in acute coronary syndrome w/out S-T-segment elevation. |
| Dosage | 75 mg once daily. |
| Administration | May be taken with or without food. |
| Contraindications | Hematopoietic disorder eg neutropenia or thrombocytopenia, hemorrhagic diathesis or other hemorrhagic disorders associated w/ prolonged bleeding time. Increased risk of bleeding e.g. GI ulcer, acute cerebral hemorrhage or severe liver dysfunction. |
| Special Precautions | Monitor blood counts within 2 wk of stopping treatment. Discontinue therapy 10-14 days pre-op. |
| Adverse Drug Reactions | GI disturbances & skin rashes. Blood dyscrasia including neutropenia & thrombotic thrombocytopenic purpura, & hemorrhagic disorders. Hepatitis & cholestatic jaundice. Increased blood-lipid conc may occur on long-term therapy. |
| Drug Interactions | Anticoagulants, antiplatelets, cimetidine, corticosteroids. |
| Pregnancy Category (US FDA) | Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
| ATC Classification | B01AC04 - Clopidogrel ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis. |
| Poison Schedule | Rx |
PACKING / PRESENTATION
| Form | Packing/Price |
| Film-coated Tablet |
75 mg x 10's 75 mg x 30's |